Reproductive BioMedicine Online
Volume 19, Issue 6 , Pages 789-795 , December 2009

Live births after management of severe OHSS by GnRH antagonist administration in the luteal phase

  • TG Lainas

      Affiliations

    • Eugonia–Iatriki Erevna IVF Centre, 7 Ventiri street, Athens, 11528, Greece
    • ,
  • IA Sfontouris

      Affiliations

    • Eugonia–Iatriki Erevna IVF Centre, 7 Ventiri street, Athens, 11528, Greece
    • ,
  • IZ Zorzovilis

      Affiliations

    • Eugonia–Iatriki Erevna IVF Centre, 7 Ventiri street, Athens, 11528, Greece
    • ,
  • GK Petsas

      Affiliations

    • Eugonia–Iatriki Erevna IVF Centre, 7 Ventiri street, Athens, 11528, Greece
    • ,
  • GT Lainas

      Affiliations

    • Eugonia–Iatriki Erevna IVF Centre, 7 Ventiri street, Athens, 11528, Greece
    • ,
  • E Alexopoulou

      Affiliations

    • 2nd Department of Radiology, Medical School, University of Athens, Attikon University Hospital, Athens, Greece
    • ,
  • EM Kolibianakis

      Affiliations

    • Unit for Human Reproduction, Medical School, Aristotle University of Thessaloniki, Greece
    • Corresponding Author InformationCorrespondence:

Received 22 January 2009 ,Revised 10 February 2009 ,Accepted 5 August 2009.

References 

  1. Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Human Reproduction Update. 2003;9:275–289
  2. Aboulghar MA, Mansour RT, Amin YM, et al. A prospective randomized study comparing coasting with GnRH antagonist administration in patients at risk for severe OHSS. Reproductive BioMedicine Online. 2007;15:271–279
  3. Amarin ZO. Bilateral partial oophorectomy in the management of severe ovarian hyperstimulation syndrome. An aggressive, but perhaps life-saving procedure. Human Reproduction. 2003;18:659–664
  4. Asch RH, Ivery G, Goldsman M, Frederick JL, et al. The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. Human Reproduction. 1993;8:1015–1020
  5. Asimakopoulos B, Nikolettos N, Nehls B, et al. Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures. Fertility and Sterility. 2006;86:636–641
  6. D’Angelo A, Amso NN. Embryo freezing for preventing ovarian hyperstimulation syndrome: a Cochrane review. Human Reproduction. 2002;17:2787–2794
  7. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Human Reproduction Update. 2002;8:559–577
  8. Delvigne A, Rozenberg S. Systematic review of data concerning etiopathology of ovarian hyperstimulation syndrome. International Journal of Fertility and Women’s Medicine. 2002;47:211–226
  9. Elizur SE, Tulandi T. Drugs in infertility and fetal safety. Fertility and Sterility. 2008;89:1595–1602
  10. Endo T, Honnma H, Hayashi T, et al. Continuation of GnRH agonist administration for 1 week, after HCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos. Human Reproduction. 2002;17:2548–2551
  11. Fatemi HM, Popovic-Todorovic B, Donoso P, et al. Luteal phase oestradiol suppression by letrozole: a pilot study in oocyte donors. Reproductive BioMedicine Online. 2008;17:307–311
  12. Fineschi V, Neri M, Di Donato S, et al. An immunohistochemical study in a fatality due to ovarian hyperstimulation syndrome. International Journal of Legal Medicine. 2006;120:293–299
  13. Garcia-Velasco JA, Quea G, Piro M, et al. Letrozole administration during the luteal phase after ovarian stimulation impacts corpus luteum function: a randomized, placebo-controlled trial. Fertility and Sterility. 2009;92:222–225
  14. Griesinger G, von Otte S, Schroer A, et al. Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study. Human Reproduction. 2007;22:1348–1352
  15. Hughes JN 2002 Ovarian stimulation for assisted reproduction technologies. In: Vayena E, Rowe PJ, Griffin PD, editors Current Practices and Controversies in Assisted Reproduction. Geneva: World Health Organization; 2002. p. 102–125.
  16. Kang IS, Kuehl TJ, Siler-Khodr TM. Effect of treatment with gonadotropin-releasing hormone analogues on pregnancy outcome in the baboon. Fertility and Sterility. 1989;52:846–853
  17. Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertility and Sterility. 2004;81:1–5
  18. Kolibianakis EM, Papanikolaou EG, Tournaye H, et al. Triggering final oocyte maturation using different doses of human chorionic gonadotropin: a randomized pilot study in patients with polycystic ovary syndrome treated with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone. Fertility and Sterility. 2007;88:1382–1388
  19. Lainas TG, Sfontouris IA, Zorzovilis IZ, et al. Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol. Reproductive BioMedicine Online. 2009;18:15–20
  20. Lainas TG, Sfontouris IA, Zorzovilis IZ, et al. Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist. Reproductive BioMedicine Online. 2007;15:408–412
  21. Lainas T, Zorzovilis J, Petsas G, et al. In a flexible antagonist protocol, earlier, criteria-based initiation of GnRH antagonist is associated with increased pregnancy rates in IVF. Human Reproduction. 2005;20:2426–2433
  22. Lainas T, Petsas G, Stavropoulou G, et al. Administration of methylprednisolone to prevent severe ovarian hyperstimulation syndrome in patients undergoing in vitro fertilization. Fertility and Sterility. 2002;78:529–533
  23. Mais V, Kazer RR, Cetel NS, et al. The dependency of folliculogenesis and corpus luteum function on pulsatile gonadotropin secretion in cycling women using a gonadotropin-releasing hormone antagonist as a probe. Journal of Clinical Endocrinology and Metabolism. 1986;62:1250–1255
  24. Minaretzis D, Jakubowski M, Mortola JF, et al. Gonadotropin-releasing hormone receptor gene expression in human ovary and granulosa-lutein cells. Journal of Clinical Endocrinology and Metabolism. 1995;80:430–434
  25. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertility and Sterility. 1992;58:249–261
  26. Porter RN, Smith W, Craft IL, et al. Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins. Lancet. 1984;2:1284–1285
  27. Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertility and Sterility. 2004;82:81–86
  28. Rizk B, Aboulghar M, Smitz J, et al. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Human Reproduction Update. 1997;3:255–266
  29. Sher G, Zouves C, Feinman M, et al. ‘Prolonged coasting’: an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization. Human Reproduction. 1995;10:3107–3109
  30. Siler-Khodr TM, Kuehl TJ, Vickery BH. Effects of a gonadotropin-releasing hormone antagonist on hormonal levels in the pregnant baboon and on fetal outcome. Fertility and Sterility. 1984;41:448–454
  31. Tavaniotou A, Devroey P. Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles. Reproductive BioMedicine Online. 2006;13:326–330
  32. Taylor PD, Hillier SG, Fraser HM. Effects of GnRH antagonist treatment on follicular development and angiogenesis in the primate ovary. Journal of Endocrinology. 2004;183:1–17

 Trifon G Lainas studied medicine at the University of Athens, Greece. He obtained his MD degree in 1973 and his PhD in 1995, also from the University of Athens. He served as Senior Registrar at Elena Venizelou Maternity Hospital from July 1979 to May 1987. He is Clinical Director at Eugonia ART Unit in Athens, Greece. His research interests are various, including optimization of ovarian stimulation protocols, ovarian hyperstimulation syndrome, reproductive endocrinology and reproductive endoscopic surgery.Dr Trifon G Lainas

PII: S1472-6483(09)00085-6

doi: 10.1016/j.rbmo.2009.09.021

Reproductive BioMedicine Online
Volume 19, Issue 6 , Pages 789-795 , December 2009

Article Tools

* Image Usage & Resolution